Replimune Group Inc (REPL)

Mar 7, 2025, 4:01 PM EST - 27 days ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 12, 2025, 4:21 PM EST - 7 weeks ago

Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 8:00 AM EST - 7 weeks ago

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 7, 2025, 4:01 PM EST - 7 weeks ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 23, 2024, 8:00 AM EST - 3 months ago

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 29, 2024, 4:12 AM EST - 4 months ago

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Nov 25, 2024, 11:55 PM EST - 4 months ago

Replimune Announces Pricing of Upsized Public Offering

Nov 25, 2024, 7:09 AM EST - 4 months ago

Replimune Announces Proposed Public Offering

Nov 21, 2024, 4:05 PM EST - 4 months ago

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Nov 9, 2024, 1:00 PM EST - 5 months ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Oct 30, 2024, 9:15 AM EDT - 5 months ago

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Sep 15, 2024, 9:45 AM EDT - 7 months ago

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 1:01 PM EDT - 7 months ago

Replimune: Strong Data In A Highly Differentiated Space

Aug 13, 2024, 8:00 AM EDT - 8 months ago

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Jul 30, 2024, 4:01 PM EDT - 8 months ago

Replimune to Present at Two Upcoming Investor Conferences

Jun 7, 2024, 8:00 AM EDT - 10 months ago

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 10 months ago

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Jun 3, 2024, 8:00 AM EDT - 10 months ago

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:00 PM EDT - 11 months ago

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 16, 2024, 8:00 AM EDT - 11 months ago

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

Apr 7, 2024, 5:00 PM EDT - 1 year ago

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Mar 26, 2024, 7:30 AM EDT - 1 year ago

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Feb 8, 2024, 8:00 AM EST - 1 year ago

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Dec 28, 2023, 8:00 AM EST - 1 year ago

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 8:28 AM EST - 1 year ago

Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals

Dec 5, 2023, 7:00 AM EST - 1 year ago

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Nov 8, 2023, 9:10 AM EST - 1 year ago

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

Nov 7, 2023, 8:00 AM EST - 1 year ago

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

Nov 3, 2023, 7:30 PM EDT - 1 year ago

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap

Oct 17, 2023, 3:00 AM EDT - 1 year ago

Tessellate BIO Emerges from Stealth

NAMS

Aug 14, 2023, 5:28 PM EDT - 1 year ago

Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch

Aug 3, 2023, 8:00 AM EDT - 1 year ago

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Jul 20, 2023, 8:00 AM EDT - 1 year ago

Replimune Announces Sander Slootweg will Depart from its Board of Directors

Jul 9, 2023, 1:22 AM EDT - 1 year ago

Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment

Jun 6, 2023, 10:00 AM EDT - 1 year ago

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

Jun 3, 2023, 2:15 PM EDT - 1 year ago

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2023, 4:01 PM EDT - 2 years ago

Replimune to Present at the Jefferies Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 18, 2023, 8:00 AM EDT - 2 years ago

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

May 15, 2023, 1:00 AM EDT - 2 years ago

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

NAMS

Feb 9, 2023, 8:00 AM EST - 2 years ago

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

Jan 3, 2023, 8:00 AM EST - 2 years ago

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 9, 2022, 2:30 PM EST - 2 years ago

Revisiting Replimune

Dec 8, 2022, 9:04 PM EST - 2 years ago

Replimune Announces Pricing of Public Offering

Dec 7, 2022, 7:00 AM EST - 2 years ago

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Dec 7, 2022, 6:30 AM EST - 2 years ago

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

Nov 3, 2022, 8:00 AM EDT - 2 years ago

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

Oct 7, 2022, 8:00 AM EDT - 2 years ago

Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Aug 12, 2022, 6:26 PM EDT - 2 years ago

Replimune: Recent Developments Strengthen Bull Thesis